Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H25N5O2.2ClH |
| Molecular Weight | 404.335 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC(C)(C)NCC(O)COC1=CC=CC=C1C2=NN=C(NN)C=C2
InChI
InChIKey=JXYMAOJZCNBDTB-UHFFFAOYSA-N
InChI=1S/C17H25N5O2.2ClH/c1-17(2,3)19-10-12(23)11-24-15-7-5-4-6-13(15)14-8-9-16(20-18)22-21-14;;/h4-9,12,19,23H,10-11,18H2,1-3H3,(H,20,22);2*1H
| Molecular Formula | C17H25N5O2 |
| Molecular Weight | 331.4127 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Prizidilol (also known as SKF 92657) is arylpyridazinylhydrazine derivative patented by Smith Kline and French Laboratories Ltd. as an antihypertensive agent. In clinical trials, Supine and standing blood pressure measured 24--27 h after drug intake was reduced Slight but significant decreases in heart rate were seen after moderate doses of prizidilol. A more pronounced blood pressure reduction was noticed 2--7 h after drug administration. Prizidilol was well tolerated, although dizziness and tiredness were reported by four patients and edema by two.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| SK&F 92657, a novel antihypertensive acting by precapillary vasodilatation and beta-adrenoreceptor blockade. | 1979 Dec |
|
| Studies on the autonomic nervous system with SK&F 92657, a new antihypertensive agent causing direct arterial vasodilatation and beta-adrenoceptor blockade. | 1981 Mar-Apr |
|
| Hemodynamic profile of a new antihypertensive agent D,L-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine (SK&F 92657). | 1981 Mar-Apr |
|
| Clinical pharmacology and pharmacokinetics of prizidilol in hypertensive patients. | 1983 Nov-Dec |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:29:21 GMT 2023
by
admin
on
Fri Dec 15 15:29:21 GMT 2023
|
| Record UNII |
U6QG1RWA7B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60979869
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
PRIMARY | |||
|
73793-66-5
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
PRIMARY | |||
|
C76558
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
PRIMARY | |||
|
U6QG1RWA7B
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
PRIMARY | |||
|
71951
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
PRIMARY | |||
|
63642-19-3
Created by
admin on Fri Dec 15 15:29:22 GMT 2023 , Edited by admin on Fri Dec 15 15:29:22 GMT 2023
|
SUPERSEDED |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |